KALA BIO Q3 2025 Earnings Report

KALA BIO EPS Results

• Actual EPS: -$53.50
• Consensus EPS: -$50.50
• Beat/Miss: Missed by -$3.00
• One Year Ago EPS: N/A

KALA BIO Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

KALA BIO Announcement Details

• Quarter: Q3 2025
• Date: 11/19/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, November 19, 2025
• Conference Call Time: 4:00PM ET

KALA BIO (NASDAQ:KALA) (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions. These include formulations under development for dry eye disease and post-operative ocular inflammation, each leveraging the company’s nanoparticle platform to achieve higher local drug concentrations while potentially reducing systemic exposure. Preclinical and clinical programs are also exploring additional indications in retinal and anterior segment disorders.

Founded in 2014 and headquartered in Watertown, Massachusetts, KALA Bio conducts research and development activities primarily in the United States. The company collaborates with academic institutions, specialty pharmacies and contract research organizations to support its clinical programs and regulatory filings. To broaden its global footprint, KALA Bio is evaluating strategic partnerships for potential expansion into European and Asian markets.